The transformative Inflation Reduction Act of 2022 is the number one trend IQVIA is following this year. Discover how the complex dynamics of Medicare Part D redesign will drive liability increases for both biopharma manufacturers and insurers. Such liabilities are expected to lead to tighter payer control and challenge brands’ gross-to-net.